CDSCO: Companies Must Report Adverse Drug Reactions Within Specified Timeframe

• CDSCO is the National Regulatory Authority (NRA) of India responsible for regulating pharmaceutical products.
• Companies manufacturing or importing drugs in India must report adverse drug reactions to CDSCO within a specified timeframe.
• Failure to comply with reporting requirements can result in severe penalties, including fines and prosecution.
• Non-reporting of adverse drug reactions can have serious consequences for public health and safety.

CDSCO has been empowered to regulate pharmaceutical products under various laws and regulations, including the Drugs and Cosmetics Act, 1940.

The Central Drugs Standard Control Organisation (CDSCO), under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, has been responsible for monitoring and regulating pharmaceutical products in the country. As the National Regulatory Authority (NRA) of India, CDSCO plays a crucial role in ensuring the safety and efficacy of drugs available in the market. However, recent data suggests that there may be gaps in the reporting of adverse drug reactions by companies operating in India.

CDSCO has been empowered to regulate pharmaceutical products under various laws and regulations, including the Drugs and Cosmetics Act, 1940. The Act mandates that all companies manufacturing or importing drugs in India must report any adverse drug reactions to CDSCO within a specified timeframe. Failure to comply with this requirement can result in severe penalties, including fines and even prosecution. Despite these provisions, there have been instances where companies have failed to report adverse drug reactions, highlighting the need for stricter enforcement and compliance measures.

The non-reporting of adverse drug reactions by companies can have serious consequences for public health and safety. If left unreported, these reactions can lead to further harm to patients, damage to the reputation of pharmaceutical companies, and even legal liability for non-compliance with regulatory requirements. As a result, lawyers should be vigilant in monitoring compliance exposure and potential liability for companies failing to report adverse drug reactions as required by CDSCO.

Lawyers should watch for compliance exposure and potential liability for companies failing to report adverse drug reactions as required by CDSCO.

Source: Original reporting via Central Drugs Standard Control Organisation (CDSCO)